Fanconi Anemia Group D2 Protein Participates in Replication Origin Firing.

J Panneerselvam, Y Shen, R Che, P Fei

Abstract read

In one paragraph

Article in Chemotherapy, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it

0cells of the map it votes in

3citing papers in PubMed

–field-weighted citation impact

1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

Multifaceted Fanconi Anemia Signaling.Trends in genetics : TIG · 2018
Review
Overlooked FANCD2 variant encodes a promising, portent tumor suppressor, and alternative polyadenylation contributes to its expression.Oncotarget · 2017
Article
TSN Disrupts Fanconi Anemia Pathway Activation Through JAK/STAT1-Mediated Transcriptional Repression of FA Core Subunits in Bladder Cancer.Dose-response : a publication of International Hormesis Society
Article

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

J PanneerselvamUniversity of Hawaii Cancer Center, 701 Ilalo Street, Honolulu, Hawai'i 96813, USA.

Y ShenUniversity of Hawaii Cancer Center, 701 Ilalo Street, Honolulu, Hawai'i 96813, USA.

R CheUniversity of Hawaii Cancer Center, 701 Ilalo Street, Honolulu, Hawai'i 96813, USA; Graduate Program of Molecular Biosciences and Bio-engineering, University of Hawaii, HI, USA.

P FeiUniversity of Hawaii Cancer Center, 701 Ilalo Street, Honolulu, Hawai'i 96813, USA; Graduate Program of Molecular Biosciences and Bio-engineering, University of Hawaii, HI, USA.

Funding

University of Hawaii Cancer Center CCSGP30CA071789 · NCI · UNIVERSITY OF HAWAII AT MANOA · PI GERTRAUD MASKARINEC · 1996 to 2026

$56.2M

Molecular Insights into the Fanconi Anemia Tumor Suppressor Signaling PathwayR01CA188251 · NCI · UNIVERSITY OF HAWAII AT MANOA · PI FEI, PEIWEN · 2014 to 2018

$1.6M

Roles of the Fanconi Anemia Pathway in Bladder TumorigenesisR01CA136532 · NCI · UNIVERSITY OF MINNESOTA · PI FEI, PEIWEN · 2009 to 2013

$1.5M

NCI NIH HHS P30 CA071789NCI NIH HHS R01 CA136532NCI NIH HHS R01 CA188251

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Identifiers

PMID27738567

DOI10.4172/2167-7700.1000206

PMCPMC5057521

What OpenQuestion holds

Textmetadata

LicenceTDM

Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.